Quarterly report pursuant to Section 13 or 15(d)

Note 12 - Intangible Assets, Net

v3.24.1.1.u2
Note 12 - Intangible Assets, Net
3 Months Ended
Mar. 31, 2024
Notes to Financial Statements  
Intangible Assets Disclosure [Text Block]

Note 12. Intangible Assets, net 

 

Intangible assets, net consisted of the following (in thousands):

 

   

March 31, 2024

 
   

(Unaudited)

 
   

Gross amount

   

Accumulated amortization

   

Net Amount

 

Pharmacy records

  $ 8,130     $ (1,219 )   $ 6,911  

Trade names

    4,700       (353 )     4,347  

Developed technology

    2,880       (432 )     2,448  

Customer Contracts

    250       (231 )     19  

Total intangible assets

  $ 15,960     $ (2,235 )   $ 13,725  

 

 

   

December 31, 2023

 
   

(Audited)

 
   

Gross amount

   

Accumulated amortization

   

Net Amount

 

Pharmacy records

  $ 8,130     $ (807 )   $ 7,323  

Trade names

    4,700       (224 )     4,476  

Developed technology

    2,880       (281 )     2,599  

Customer Contracts

    250       (225 )     25  

Total intangible assets

  $ 15,960     $ (1,537 )   $ 14,423  

 

Amortization of customer contracts is included in depreciation and amortization in the accompanying Condensed Consolidated Statements of Comprehensive Income (Loss). For the three months ended March 31, 2024 and 2023, the Company recognized amortization expense of approximately $0.7 million and $0.01 million, respectively. Future amortization of intangible assets is as follows:

 

Year

    Amount  

2024 (remaining nine months)

  $ 2,023  

2025

    2,672  

2026

    2,672  

2027

    2,672  

2028

    1,571  

Thereafter

    2,115  

Total

  $ 13,725